Series C2 · BiotechAntheia: Series C2Produces high-value pharmaceutical ingredients using advanced biosynthesisPublished Oct 4, 2026By RoundOS Funding deskFunding historyJan 27, 2026Series C2 · This round$24MSourcesprnewswire.com↗
AusperBioDevelops oligonucleotide therapeutics targeting chronic hepatitis B$120MSeries C · Aug 27, 2026
ProFound TherapeuticsUses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia$35MStrategic · Aug 27, 2026
TransfyrPhysical AI platform capturing real-world lab science into machine-readable data$25MSeed · Aug 26, 2026
Airway TherapeuticsDevelops biologic therapies for respiratory and infectious diseases$50MSeries E2 · Aug 25, 2026